Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cytokinetics: An Update Based on CEO Robert Blum’s Comments at BIO CEO Conference on February 8, 2016 (CYTK, Buy, $6.57)

Summary

I attended the BIO CEO conference in New York City on February 8 and 9. I am writing a series…
Read more…

Cytokinetics: Takeaways from Recent R&D Day and Reiteration of Buy (CYTK, $6.14, Buy)

Investment Overview

I find the recent stock weakness in Cytokinetics perplexing. The Company has a market value of about $300 million…
Read more…

Cytokinetics: Takeaways from January 5, 2014 Conference Call (CYTK, Buy, $7.82)

Cytokinetics held a conference call on January 5th in which they added some detail on the collaboration with Astellas on…
Read more…